In fact, results from the INTELLANCE 2 trial with the late-stage candidate depatuxizumab mafodotin (ABT-414; Deputax-M) in combination with temozolomide showed OS improvement in epidermal growth factor receptor (EGFR)-amplified recurrent glioblastoma [93]. The gene discussed is EGFR; the disease is glioblastoma.